2023 Speakers

 

Suchismita Acharya, Chief Executive Officer, AyuVis Research

Suchismita Acharya | Chief Executive Officer | AyuVis Research » speaking at Orphan Drug Congress

Alex Aimetti, Head Of Scientific Affairs, Marinus Pharmaceuticals

Alex Aimetti | Head Of Scientific Affairs | Marinus Pharmaceuticals » speaking at Orphan Drug Congress

Paul Aliu, Head Global Governance Office, Novartis Chief Medical Office (CMO), Novartis

Paul Aliu | Head Global Governance Office, Novartis Chief Medical Office (CMO) | Novartis » speaking at Orphan Drug Congress

Simon Andrews, Senior Vice President, Head of Analytics, EVERSANA

Simon Andrews | Senior Vice President, Head of Analytics | EVERSANA » speaking at Orphan Drug Congress

Irina Antonijevic, Chief Medical Officer, EveryONE Medicines

Irina Antonijevic | Chief Medical Officer | EveryONE Medicines » speaking at Orphan Drug Congress

Andrew Auruku, Chief Executive Officer, Rare Diseases Uganda-RDU

Andrew Auruku | Chief Executive Officer | Rare Diseases Uganda-RDU » speaking at Orphan Drug Congress

Ron Bartek, President, Director, And Founder, Friedreich's Ataxia Research Alliance

Ron Bartek | President, Director, And Founder | Friedreich's Ataxia Research Alliance » speaking at Orphan Drug Congress

Norman Barton, Chair of the Clinical and Scientific Advisory Board, Oak Hill Bio

Norman Barton | Chair of the Clinical and Scientific Advisory Board | Oak Hill Bio » speaking at Orphan Drug Congress

Scott Bergeron, Partner, Clinical Research, iTakeControl, a Red Nucleus Company

Scott Bergeron | Partner, Clinical Research | iTakeControl, a Red Nucleus Company » speaking at Orphan Drug Congress

Alexandre Betourne, Scientific Director, Critical Path Institute

Alexandre Betourne | Scientific Director | Critical Path Institute » speaking at Orphan Drug Congress

Sulagna Bhattacharya, Executive Officer & Co-Founder, NanoScope Technologies

Sulagna Bhattacharya | Executive Officer & Co-Founder | NanoScope Technologies » speaking at Orphan Drug Congress

Henric Bjarke, Chief Operating Officer, Inozyme

Henric Bjarke | Chief Operating Officer | Inozyme » speaking at Orphan Drug Congress

Wendy Borsari, Senior Manager of Patient Advocacy, Tenaya Therapeutics

Wendy Borsari | Senior Manager of Patient Advocacy | Tenaya Therapeutics » speaking at Orphan Drug Congress

Imein Bousnina, Program Director, US Regulatory Policy, Product Development Regulatory, Genentech

Imein Bousnina | Program Director, US Regulatory Policy, Product Development Regulatory | Genentech » speaking at Orphan Drug Congress

Marie Brace, Patient Access Liaison, Catalyst Pharmaceutical Partners

Marie Brace | Patient Access Liaison | Catalyst Pharmaceutical Partners » speaking at Orphan Drug Congress

Julie Breneiser, Executive Director, Gorlin Syndrome Alliance

Julie Breneiser | Executive Director | Gorlin Syndrome Alliance » speaking at Orphan Drug Congress

Larry Bressler, Head of Value and Market Access, Chiesi Global Rare Diseases

Larry Bressler | Head of Value and Market Access | Chiesi Global Rare Diseases » speaking at Orphan Drug Congress

Matthias Breugelmans, CEO, Elastrin Therapeutics

Matthias Breugelmans | CEO | Elastrin Therapeutics » speaking at Orphan Drug Congress

Rusty Bromley, Director of Operations, AyuVis Research, Inc.

Rusty Bromley | Director of Operations | AyuVis Research, Inc. » speaking at Orphan Drug Congress

PJ Brooks, Health Scientist Administrator, NIH/NCATS

PJ Brooks | Health Scientist Administrator | NIH/NCATS » speaking at Orphan Drug Congress

Robert Buchanan, Founder And Partner, Ventac Partners

Robert Buchanan | Founder And Partner | Ventac Partners » speaking at Orphan Drug Congress

Lynn Bush, Bioethicist-Developmental Research Scientist, Division of Genetics and Genomics, Pediatrics and Center for Bioethics, Harvard Medical School and Boston Children’s Hospital

Lynn Bush | Bioethicist-Developmental Research Scientist, Division of Genetics and Genomics, Pediatrics and Center for Bioethics | Harvard Medical School and Boston Children’s Hospital » speaking at Orphan Drug Congress

Leonardo Calzetti, Co-founding Director & Sr. Partner, BlueDil International

Leonardo Calzetti | Co-founding Director & Sr. Partner | BlueDil International » speaking at Orphan Drug Congress

Grant Castor, SVP Commercial Strategy & Operations, Sentynl Therapeutics

Grant Castor | SVP Commercial Strategy & Operations | Sentynl Therapeutics » speaking at Orphan Drug Congress

Ms Afshawn Chakamian, Director of Therapeutic Expertise, Center for Rare Diseases, DDS, ICON

Ms Afshawn Chakamian | Director of Therapeutic Expertise, Center for Rare Diseases, DDS | ICON » speaking at Orphan Drug Congress

Ms Anne-Sophie Chalandon, Head of Rare Diseases Global Public Affairs Rare Disease and ATMP Policy at Sanofi, Vice-Chair of the EFPIA OMP WG, Sanofi

Ms Anne-Sophie Chalandon | Head of Rare Diseases Global Public Affairs Rare Disease and ATMP Policy at Sanofi, Vice-Chair of the EFPIA OMP WG | Sanofi » speaking at Orphan Drug Congress

Mr David Chapman, Vice President of Market Access, Agios Pharmaceuticals

Mr David Chapman | Vice President of Market Access | Agios Pharmaceuticals » speaking at Orphan Drug Congress

Nitin Choudhary, Vice President, IPM.ai

Nitin Choudhary | Vice President | IPM.ai » speaking at Orphan Drug Congress

Steven Cohen, Executive Director, Translational Medicine-Oncology & Internal Medicine, & Search & Evaluation-IM, Daiichi Sankyo

Steven Cohen | Executive Director, Translational Medicine-Oncology & Internal Medicine, & Search & Evaluation-IM | Daiichi Sankyo » speaking at Orphan Drug Congress

Ashley Cox, Senior Principal, Head of Europe | President HBA - London Chapter, EVERSANA

Ashley Cox | Senior Principal, Head of Europe | President HBA - London Chapter | EVERSANA » speaking at Orphan Drug Congress

Carole Cramer, CEO and CoFounder, Biostrategies

Carole Cramer | CEO and CoFounder | Biostrategies » speaking at Orphan Drug Congress

Joslyn Crowe, Executive Director, National Niemann Pick Disease Foundation Inc

Joslyn Crowe | Executive Director | National Niemann Pick Disease Foundation Inc » speaking at Orphan Drug Congress

John F. Crowley, Chairman and Chief Executive Officer, Amicus Therapeutics Inc

John F. Crowley | Chairman and Chief Executive Officer | Amicus Therapeutics Inc » speaking at Orphan Drug Congress

Charlotte Damiano, Global Regulatory Partner, Life Sciences, Hogan Lovells

Charlotte Damiano | Global Regulatory Partner, Life Sciences | Hogan Lovells » speaking at Orphan Drug Congress

Michelle Davis, Executive Director, International Fibrodysplasia Ossificans Progressiva Association

Michelle Davis | Executive Director | International Fibrodysplasia Ossificans Progressiva Association » speaking at Orphan Drug Congress

Lisa Deschamps, Chief Executive Officer, AviadoBio

Lisa Deschamps | Chief Executive Officer | AviadoBio » speaking at Orphan Drug Congress

Chowdary Dondapati, Executive Director, US Head of Diagnostic Marketing, Precision Medicine, Bayer

Chowdary Dondapati | Executive Director, US Head of Diagnostic Marketing, Precision Medicine | Bayer » speaking at Orphan Drug Congress

Michael Dudley, Chief Executive Officer and Co-founder, TransCode Therapeutics

Michael Dudley | Chief Executive Officer and Co-founder | TransCode Therapeutics » speaking at Orphan Drug Congress

Sean Ekins, Chief Executive Officer, Collaborations Pharmaceuticals

Sean Ekins | Chief Executive Officer | Collaborations Pharmaceuticals » speaking at Orphan Drug Congress

Lisa Feng, Senior Director, Health Policy, Alexion – AstraZeneca Rare Disease

Lisa Feng | Senior Director, Health Policy | Alexion – AstraZeneca Rare Disease » speaking at Orphan Drug Congress

Holly Fernandez Lynch, Department of Medical Ethics & Health Policy, University of Pennsylvania

Holly Fernandez Lynch | Department of Medical Ethics & Health Policy | University of Pennsylvania » speaking at Orphan Drug Congress

Sylvain Forget, Chief Executive Officer, BlueDil International

Sylvain Forget | Chief Executive Officer | BlueDil International » speaking at Orphan Drug Congress

Al Freedman, Counseling Psychologist, Freedman Counseling Associates

Al Freedman | Counseling Psychologist | Freedman Counseling Associates » speaking at Orphan Drug Congress

Michele Gerber, Chief Medical Officer, Myeloid Therapeutics

Michele Gerber | Chief Medical Officer | Myeloid Therapeutics » speaking at Orphan Drug Congress

Erin Griner, Assistant Director of Clinical Research Methodology, Worldwide Clinical Trials

Erin Griner | Assistant Director of Clinical Research Methodology | Worldwide Clinical Trials » speaking at Orphan Drug Congress

Amy Grover, Director of Patient Advocacy, Catalyst Pharmaceutical Partners

Amy Grover | Director of Patient Advocacy | Catalyst Pharmaceutical Partners » speaking at Orphan Drug Congress

Mr Maria Hadjidemetriou, Specialist Management Account, Medscheme Holdings (Pty) Ltd

Mr Maria Hadjidemetriou | Specialist Management Account | Medscheme Holdings (Pty) Ltd » speaking at Orphan Drug Congress

Alaa Hamed, Global Head of Medical Affairs Rare Diseases, Sanofi

Alaa Hamed | Global Head of Medical Affairs Rare Diseases | Sanofi » speaking at Orphan Drug Congress

Molly Harper, Chief Business Officer, Synlogic

Molly Harper | Chief Business Officer | Synlogic » speaking at Orphan Drug Congress

Rachel Harrison, Associate Director, Early Access Programs, Apellis Pharmaceuticals, Inc

Rachel Harrison | Associate Director, Early Access Programs | Apellis Pharmaceuticals, Inc » speaking at Orphan Drug Congress

Lauren Heiser, Business Development Director, Clinigen Group

Lauren Heiser | Business Development Director | Clinigen Group » speaking at Orphan Drug Congress

Terry Hermiston, Chief Executive Officer, GLAdiator Biosciences and Coagulant Therapeutics, Inc

Terry Hermiston | Chief Executive Officer | GLAdiator Biosciences and Coagulant Therapeutics, Inc » speaking at Orphan Drug Congress

Sharon Hesterlee, Chief Research Officer, MDA

Sharon Hesterlee | Chief Research Officer | MDA » speaking at Orphan Drug Congress

Kenneth Hobby, President, Cure SMA

Kenneth Hobby | President | Cure SMA » speaking at Orphan Drug Congress

Dwain Irvin, Chief Executive Officer, NovAccess Global, Inc

Dwain Irvin | Chief Executive Officer | NovAccess Global, Inc » speaking at Orphan Drug Congress

Hearn Jay Cho, Chief Medical Officer, Multiple Myeloma Research Foundation

Hearn Jay Cho | Chief Medical Officer | Multiple Myeloma Research Foundation » speaking at Orphan Drug Congress

Judith Kelleher-Andersson, President and Chief Executive Officer-Neuronascent, NeuroNascent Inc

Judith Kelleher-Andersson | President and Chief Executive Officer-Neuronascent | NeuroNascent Inc » speaking at Orphan Drug Congress

Ken Kengatharan, Managing General Partner, Atheneos Ventures

Ken Kengatharan | Managing General Partner | Atheneos Ventures » speaking at Orphan Drug Congress

Annie Kennedy, Chief of Policy, Advocacy, & Patient Engagement,, EveryLife Foundation for Rare Diseases

Annie Kennedy | Chief of Policy, Advocacy, & Patient Engagement, | EveryLife Foundation for Rare Diseases » speaking at Orphan Drug Congress

Maria Kirsch, General Manager, Patient Services, EVERSANA

Maria Kirsch | General Manager, Patient Services | EVERSANA » speaking at Orphan Drug Congress

Terri Klein, President And Chief Executive Officer, National M.P.S. Society

Terri Klein | President And Chief Executive Officer | National M.P.S. Society » speaking at Orphan Drug Congress

Bryan Kobel, Chief Executive Officer, TC Biopharm

Bryan Kobel | Chief Executive Officer | TC Biopharm » speaking at Orphan Drug Congress

Augusta Elizabeth Koroma, Chief Executive Officer, Sickle cell Intervention U.K

Augusta Elizabeth Koroma | Chief Executive Officer | Sickle cell Intervention U.K » speaking at Orphan Drug Congress

Kollet Koulianos, Vice President Payer Relations, The National Hemophilia Foundation

Kollet Koulianos | Vice President Payer Relations | The National Hemophilia Foundation » speaking at Orphan Drug Congress

Walter Kowtoniuk, Venture Partner, Third Rock Ventures, LLC

Walter Kowtoniuk | Venture Partner | Third Rock Ventures, LLC » speaking at Orphan Drug Congress

Henrik Krook, Vice President Of Commercial Operations, Egetis Therapeutics AB

Henrik Krook | Vice President Of Commercial Operations | Egetis Therapeutics AB » speaking at Orphan Drug Congress

Larissa Lapteva, Associate Director, FDA

Larissa Lapteva | Associate Director | FDA » speaking at Orphan Drug Congress

Cath Lawrence, VP, Rare Disease, Bionical Emas

Cath Lawrence | VP, Rare Disease | Bionical Emas » speaking at Orphan Drug Congress

Del Lebel, Head, US Government Affairs and Policy, Alexion – AstraZeneca Rare Disease

Del Lebel | Head, US Government Affairs and Policy | Alexion – AstraZeneca Rare Disease » speaking at Orphan Drug Congress

Connie Lee, President And Chief Executive Officer, Alliance to Cure Cavernous Malformations

Connie Lee | President And Chief Executive Officer | Alliance to Cure Cavernous Malformations » speaking at Orphan Drug Congress

Naomi Litchfield, Global Patient Advocacy Lead, Bionical Emas

Naomi Litchfield | Global Patient Advocacy Lead | Bionical Emas » speaking at Orphan Drug Congress

Jeff Livingstone, Chief Executive Officer, Igia Pharmaceuticals

Jeff Livingstone | Chief Executive Officer | Igia Pharmaceuticals » speaking at Orphan Drug Congress

Robert Long, Executive Director, Uplifting Athletes

Robert Long | Executive Director | Uplifting Athletes » speaking at Orphan Drug Congress

Mark Manfredi, CEO, Ikena Oncology

Mark Manfredi | CEO | Ikena Oncology » speaking at Orphan Drug Congress

Peter Marks, Director, Center For Biologics Evaluation And Research (CBER), U.S. Food and Drug Administration

Peter Marks | Director, Center For Biologics Evaluation And Research (CBER) | U.S. Food and Drug Administration » speaking at Orphan Drug Congress

Silas Martin, Senior Director, Market Access Scientific And External Strategy, Johnson & Johnson

Silas Martin | Senior Director, Market Access Scientific And External Strategy | Johnson & Johnson » speaking at Orphan Drug Congress

Paolo Martini, Chief Scientific Officer Rare Diseases, Hematology and External R&D, Moderna, Inc.

Paolo Martini | Chief Scientific Officer Rare Diseases, Hematology and External R&D | Moderna, Inc. » speaking at Orphan Drug Congress

Cara Mayfield, VP, Patient Advocacy and Corporate Communications, Homology Medicines

Cara Mayfield | VP, Patient Advocacy and Corporate Communications | Homology Medicines » speaking at Orphan Drug Congress

Maria Mccaffrey, Vice President Country Regulatory and Quality, Alexion – AstraZeneca Rare Disease

Maria Mccaffrey | Vice President Country Regulatory and Quality | Alexion – AstraZeneca Rare Disease » speaking at Orphan Drug Congress

Kim McClellan, President, Recurrent Respiratory Papillomatosis Foundation

Kim McClellan | President | Recurrent Respiratory Papillomatosis Foundation » speaking at Orphan Drug Congress

Susan Mccune, Vice President, Pediatrics & Clinical Pharmacology, Thermo Fisher Scientific

Susan Mccune | Vice President, Pediatrics & Clinical Pharmacology | Thermo Fisher Scientific » speaking at Orphan Drug Congress

Jennifer McNary, Founder, One Rare

Jennifer McNary | Founder | One Rare » speaking at Orphan Drug Congress

Christine McSherry, Executive Director, Strategic Collaborations, The Emmes Company, LLC

Christine McSherry | Executive Director, Strategic Collaborations | The Emmes Company, LLC » speaking at Orphan Drug Congress

Tsveta Milanova, Chief Commercial Officer, Agios

Tsveta Milanova | Chief Commercial Officer | Agios » speaking at Orphan Drug Congress

Timothy Miller, Global Vice President, PPD, part of Thermo Fisher Scientific

Timothy Miller | Global Vice President | PPD, part of Thermo Fisher Scientific » speaking at Orphan Drug Congress

Samarendra Mohanty, Founder-President, Chief Scientific Officer, nanoscope therapeutics

Samarendra Mohanty | Founder-President, Chief Scientific Officer | nanoscope therapeutics » speaking at Orphan Drug Congress

Mona Moonis, NA Brand Lead, Rare Disease, Kyowa Kirin

Mona Moonis | NA Brand Lead, Rare Disease | Kyowa Kirin » speaking at Orphan Drug Congress

Annette Muaghan, Co-Founder And Chief Executive Officer, KBG Foundation

Annette Muaghan | Co-Founder And Chief Executive Officer | KBG Foundation » speaking at Orphan Drug Congress

Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)

Alexander Natz | Secretary General | European Confederation of Pharmaceutical Entrepreneurs (Belgium) » speaking at Orphan Drug Congress

George Naumov, Chief Business Officer, RS Oncology

George Naumov | Chief Business Officer | RS Oncology » speaking at Orphan Drug Congress

Adora Ndu, Chief Regulatory and interim Legal Officer, BridgeBio Gene Therapy

Adora Ndu | Chief Regulatory and interim Legal Officer | BridgeBio Gene Therapy » speaking at Orphan Drug Congress

Galina Nesterova, Executive Medical Director- Rare Diseases & Pediatrics, PPD, part of Thermo Fisher Scientific

Galina Nesterova | Executive Medical Director- Rare Diseases & Pediatrics | PPD, part of Thermo Fisher Scientific » speaking at Orphan Drug Congress

Victoria Niklas, Chief Medical Officer, Oak Hill Bio

Victoria Niklas | Chief Medical Officer | Oak Hill Bio » speaking at Orphan Drug Congress

Lisa Padilla, Chief Executive Officer, Beryl Therapeutics Inc

Lisa Padilla | Chief Executive Officer | Beryl Therapeutics Inc » speaking at Orphan Drug Congress

Kinnari Patel, President & COO, Rocket Pharma

Kinnari Patel | President & COO | Rocket Pharma » speaking at Orphan Drug Congress

Melissa Penn, Director Patient Engagement Research & Development, Bayer

Melissa Penn | Director Patient Engagement Research & Development | Bayer » speaking at Orphan Drug Congress

Richie Pfeiffer, Senior Director- Decentralized Clinical Trials, PPD, part of Thermo Fisher Scientific

Richie Pfeiffer | Senior Director- Decentralized Clinical Trials | PPD, part of Thermo Fisher Scientific » speaking at Orphan Drug Congress

Damon Race, President & CEO, GeneVentiv Therapeutics, Inc

Damon Race | President & CEO | GeneVentiv Therapeutics, Inc » speaking at Orphan Drug Congress

Paula Ragan, President and CEO, X4 Pharmaceuticals

Paula Ragan | President and CEO | X4 Pharmaceuticals » speaking at Orphan Drug Congress

Amy Raymond, Senior Director, Therapeutic Strategy Lead, Rare Diseases, Worldwide Clinical Trials

Amy Raymond | Senior Director, Therapeutic Strategy Lead, Rare Diseases | Worldwide Clinical Trials » speaking at Orphan Drug Congress

Frank Rivera, President, Stronger Than Sarcoidosis

Frank Rivera | President | Stronger Than Sarcoidosis » speaking at Orphan Drug Congress

Priscilla Rodriguez, Diversity Inclusion Advocacy Manager, EveryLife Foundation for Rare Diseases

Priscilla Rodriguez | Diversity Inclusion Advocacy Manager | EveryLife Foundation for Rare Diseases » speaking at Orphan Drug Congress

Kacper Rucinski, Delegate, SMA Europe / Founder, Member of Strategy Board, SMA Foundation Poland, SMA Europe (Germany) / SMA Foundation (Poland)

Kacper Rucinski | Delegate, SMA Europe / Founder, Member of Strategy Board, SMA Foundation Poland | SMA Europe (Germany) / SMA Foundation (Poland) » speaking at Orphan Drug Congress

Christopher Rudolf, Chief Executive Officer and Founder, volv global

Christopher Rudolf | Chief Executive Officer and Founder | volv global » speaking at Orphan Drug Congress

Sandhya Sanduja, Acting Branch Chief, Pharmacology/Toxicology Branch1, Office of Tissues and Advanced Therapies, CBER,, FDA

Sandhya Sanduja | Acting Branch Chief, Pharmacology/Toxicology Branch1, Office of Tissues and Advanced Therapies, CBER, | FDA » speaking at Orphan Drug Congress

Jonathan Schwartz, Chief Medical Officer, Rocket Pharma

Jonathan Schwartz | Chief Medical Officer | Rocket Pharma » speaking at Orphan Drug Congress

Denise Scots Knight, Chief Executive Officer, Mereo Biopharma

Denise Scots Knight | Chief Executive Officer | Mereo Biopharma » speaking at Orphan Drug Congress

Albert Seymour, Chief Scientific Officer, Homology Medicines

Albert Seymour | Chief Scientific Officer | Homology Medicines » speaking at Orphan Drug Congress

Nilomi Shah, Director of Medical Affairs Lead, Lexeo Therapeutics

Nilomi Shah | Director of Medical Affairs Lead | Lexeo Therapeutics » speaking at Orphan Drug Congress

Pallavi Sharma, Senior Manager, Scientific Project And Pharmaceutical Development, Adverum Biotechnologies

Pallavi Sharma | Senior Manager, Scientific Project And Pharmaceutical Development | Adverum Biotechnologies » speaking at Orphan Drug Congress

Jerry Shen, CEO, Co-Founder, AceLink Therapeutics, Inc

Jerry Shen | CEO, Co-Founder | AceLink Therapeutics, Inc » speaking at Orphan Drug Congress

Tricha Shivas, Chief Strategy Officer, Foundation for Sarcoidosis Research

Tricha Shivas | Chief Strategy Officer | Foundation for Sarcoidosis Research » speaking at Orphan Drug Congress

Wen Chyi Shyu, Chief Executive Officer, BRIM Biotechnology, Inc.

Wen Chyi Shyu | Chief Executive Officer | BRIM Biotechnology, Inc. » speaking at Orphan Drug Congress

Ms Amy Simon, Chief Medical Officer, Beam Therapeutics

Ms Amy Simon | Chief Medical Officer | Beam Therapeutics » speaking at Orphan Drug Congress

Nick Sireau, Chair and Chief Executive Officer, AKU Society

Nick Sireau | Chair and Chief Executive Officer | AKU Society » speaking at Orphan Drug Congress

Jayson Slotnik, Partner, Health Policy Strategies, LLC

Jayson Slotnik | Partner | Health Policy Strategies, LLC » speaking at Orphan Drug Congress

Tom Smith, Project Development Specialist, Durbin

Tom Smith | Project Development Specialist | Durbin » speaking at Orphan Drug Congress

Mr Kim Smith-Whitley, Executive Vice President and Head of Research and Development, Global Blood Therapeutics, Inc.

Mr Kim Smith-Whitley | Executive Vice President and Head of Research and Development | Global Blood Therapeutics, Inc. » speaking at Orphan Drug Congress

Scott Snyder, Chief Digital Officer, EVERSANA

Scott Snyder | Chief Digital Officer | EVERSANA » speaking at Orphan Drug Congress

Kim Stephens, President, Project Alive

Kim Stephens | President | Project Alive » speaking at Orphan Drug Congress

Dean Suhr, President, MLD Foundation

Dean Suhr | President | MLD Foundation » speaking at Orphan Drug Congress

Jamie Sullivan, Director of Public Policy, EveryLife Foundation for Rare Diseases

Jamie Sullivan | Director of Public Policy | EveryLife Foundation for Rare Diseases » speaking at Orphan Drug Congress

Marshall Summar, Director, Rare Disease Institute, Children's National Medical Center

Marshall Summar | Director, Rare Disease Institute | Children's National Medical Center » speaking at Orphan Drug Congress

Mitra Tavakkoli, Vice President; Clinical Development, 4DMT

Mitra Tavakkoli | Vice President; Clinical Development | 4DMT » speaking at Orphan Drug Congress

Ulrich Thienel, Chief Executive Officer, ReAlta Life Sciences

Ulrich Thienel | Chief Executive Officer | ReAlta Life Sciences » speaking at Orphan Drug Congress

Mark Trusheim, Strategic Director, MIT NEWDIGS

Mark Trusheim | Strategic Director | MIT NEWDIGS » speaking at Orphan Drug Congress

Andrew Udell, President of North America, Commercial, Calliditas Therapeutics

Andrew Udell | President of North America, Commercial | Calliditas Therapeutics » speaking at Orphan Drug Congress

Robert-Jan Van Son, General Manager Germany, BeNeLux and Nordic,, Orphalan

Robert-Jan Van Son | General Manager Germany, BeNeLux and Nordic, | Orphalan » speaking at Orphan Drug Congress

Atul Varadhachary, Managing Partner, Fannin Innovation Studio

Atul Varadhachary | Managing Partner | Fannin Innovation Studio » speaking at Orphan Drug Congress

Lavni Varyani, Founder, Pharma BP DMCC

Lavni Varyani | Founder | Pharma BP DMCC » speaking at Orphan Drug Congress

Geeta Vemuri, Managing Partner, Agent Capital

Geeta Vemuri | Managing Partner | Agent Capital » speaking at Orphan Drug Congress

Daniel Wainstock, Law student, PUC-Rio

Daniel Wainstock | Law student | PUC-Rio » speaking at Orphan Drug Congress

Terence Walts, Chief Executive Officer, Cambium Medical Technologies

Terence Walts | Chief Executive Officer | Cambium Medical Technologies » speaking at Orphan Drug Congress

Jingsong Wang, President & Chief Executive Officer, Harbour Biomed

Jingsong Wang | President & Chief Executive Officer | Harbour Biomed » speaking at Orphan Drug Congress

Mary Wang, Programme Director, Rare Diseases International

Mary Wang | Programme Director | Rare Diseases International » speaking at Orphan Drug Congress

Ryan Witt, Chief Business Officer, Spinogenix

Ryan Witt | Chief Business Officer | Spinogenix » speaking at Orphan Drug Congress

Durhane Wong-Rieger, President, Canadian Organization for Rare Disorders

Durhane Wong-Rieger | President | Canadian Organization for Rare Disorders » speaking at Orphan Drug Congress

Lisa Yañez, Chief Executive Officer, Aerami Therapeutics

Lisa Yañez | Chief Executive Officer | Aerami Therapeutics » speaking at Orphan Drug Congress

David Young, Chief Executive Officer, Processa Pharmaceuticals, Inc.

David Young | Chief Executive Officer | Processa Pharmaceuticals, Inc. » speaking at Orphan Drug Congress

Ms Jennifer Young, Senior Director and Lead, Policy and Public Affairs Emerging Asia, Pfizer

Ms Jennifer Young | Senior Director and Lead, Policy and Public Affairs Emerging Asia | Pfizer » speaking at Orphan Drug Congress

Get Involved At World Orphan Drug Congress USA

 

To Sponsor Or Exhibit

 
 

Justin Franks
justin.franks@terrapinn.com
t/ +1 914 819 3506

 

 

 

To Speak

 
 

Claire Murphy
claire.murphy@terrapinn.com
t/ +1 646 619 1784

 

 

 

Marketing & Press Opportunities

 
 

Taylor Post
taylor.post@terrapinn.com
t/ +1 646 619 1785